Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium

Relationship to Family History and Conversion to Psychosis

Larry J. Seidman, PhD; Anthony J. Giuliano, PhD; Eric C. Meyer, PhD; Jean Addington, PhD; Kristin S. Cadenhead, MD; Tyrone D. Cannon, PhD; Thomas H. McGlashan, MD; Diana O. Perkins, MD, MPH; Ming T. Tsuang, MD, PhD; Elaine F. Walker, PhD; Scott W. Woods, MD; Carrie E. Bearden, PhD; Bruce K. Christensen, PhD; Keith Hawkins, PsyD; Robert Heaton, PhD; Richard S. E. Keefe, PhD; Robert Heinssen, PhD; Barbara A. Cornblatt, PhD, MBA; for the North American Prodrome Longitudinal Study (NAPLS) Group

Context: Early detection and prospective evaluation of clinical high-risk (CHR) individuals who may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset and for testing preventive interventions.

Objectives: To elucidate the neuropsychology of the CHR syndrome, to determine the association of neuropsychological function with conversion to psychosis and family history of psychosis, and to examine whether baseline neuropsychological functioning predicts subsequent psychosis.

Design: Longitudinal study with 2½ years of follow-up.

Setting: Eight centers participating in the North American Prodrome Longitudinal Study.

Participants: Three hundred four prospectively identified CHR individuals meeting Structured Interview for Prodromal Syndromes criteria, 52 non-CHR persons with a family history of psychosis in first- or second-degree relatives (family high-risk group), and 193 normal controls with neither a family history of psychosis nor a CHR syndrome, all of whom underwent baseline neuropsychological evaluations.

Main Outcome Measures: A neurocognitive composite score, 8 individual neuropsychological measures, an IQ estimate, and high-risk status.

Results: Global (“composite”) neuropsychological functioning was comparably impaired in the CHR and family high-risk groups compared with controls, but profiles differed significantly between groups. Neuropsychological functioning in the CHR group was significantly lower in persons who progressed to psychosis than in those who did not and was worst in the subgroup with a family history of psychosis. Tests of processing speed and verbal learning and memory were most sensitive in discriminating CHR individuals from controls, although reductions were less severe than in established schizophrenia. Neuropsychological functioning did not contribute uniquely to the prediction of psychosis beyond clinical criteria, but worse verbal memory predicted more rapid conversion.

Conclusions: These findings document that CHR individuals have significant neuropsychological difficulties, particularly those who later develop psychosis. This dysfunction is generally of moderate severity but less than in first-episode schizophrenia, suggesting that further decline may occur after baseline CHR assessment.

Arch Gen Psychiatry. 2010;67(6):578-588

SUBSTANTIAL NEUROPSYCHOLOGICAL deficits, first described by Kraepelin1 and Bleuler,2 have subsequently been observed in all phases of schizophrenia, beginning in the premorbid period and continuing throughout life. Patients in the first psychotic episode and during chronic periods manifest large neuropsychological impairments with effect sizes (ESs) averaging approximately 1.0.3 The degree of impairment depends on the domain measured, with verbal memory and processing speed typically eliciting the largest deficits (ES, 1.3–1.6 by Cohen d).4 Moreover, because neuropsychological functions are important as windows into pathophysiology5 and because they are strongly associated with functional outcomes in schizophrenia,6 they may be important in risk prediction of psychosis.

The robust finding of premorbid neuropsychological impairment indicates that these measures may have utility as predictors of schizophrenia, an idea frequently evaluated in persons at genetic (familial) high risk (FHR),7,8 and recently in clinical high-risk (CHR) or putatively “prodromal” samples.9 Clinical high risk requires the presence of specific subsyndromal psychotic symptoms, while FHR is defined solely by the presence of a family history (FH) of psychosis.

Compared with healthy control subjects, ESs of neuropsychological deficits in...
offsprings and adult nonpsychotic relatives of persons with schizophrenia range between 0.3 and 0.6, reflecting moderate deficits in the absence of psychosis. These findings suggest that cognitive deficits are associated with the neural substrates of the illness and that they may be attributable largely to inherited variations. These impairments have considerable validity because they are not confounded by psychosis or medication. Commonly identified deficits in FHR samples include lower verbal ability, general intelligence (IQ), declarative and working memory, sustained attention, processing speed, and executive and motor functions.

While identification of neuropsychological impairments in FHR samples supports a neurodevelopmental model of vulnerability to schizophrenia, their utility for prediction of psychosis is limited by modest lifetime conversion rates of approximately 10%. The problem of relatively low conversion rates in FHR samples and the notion that early detection and intervention may prevent clinical expression of psychosis or functional deterioration have stimulated a new direction in psychiatry research aimed at reducing morbidity and mortality, similar to prevention efforts in other branches of medicine. This approach has focused on developing and validating criteria for ascertaining individuals at risk of imminent onset of psychosis and observing them over time. Advantages of this approach over FHR methods include more efficient timing of assessments proximate to illness onset and reduction of false-positive rates. Because the modal period of onset in schizophrenia is between ages 18 and 30 years, “case identification” during adolescence and young adulthood is essential.

During the past 5 years, at least 10 research groups have published studies of neuropsychological functioning in CHR samples. Findings from cross-sectional CHR studies have consistently documented that neuropsychological deficits are intermediate between control and first-episode psychosis samples, and one has shown that neuropsychological functioning is related to illness course. Several specific deficits have been observed, most reliably in spatial and verbal working memory, verbal declarative memory, and attention. Deficits in olfaction and executive functions, as measured by verbal fluency, matrices, and set shifting, and visual form perception have been less consistently tested or identified. Some deficits (e.g., in sustained attention) may represent stable vulnerability markers, while others (such as in verbal memory, working memory, processing speed, and verbal IQ) may be predictive of conversion to psychosis.

Despite substantial progress, variability in test batteries and small samples complicate interpretation. Moreover, only 2 studies have integrated FHR and CHR methods, and the few studies that compared individuals who did and did not convert to illness were limited by small samples and brief follow-ups. Because many patients with neuropsychiatric disorders manifest neuropsychological deficits, it is important to compare CHR individuals who develop psychosis with those who do not. Longitudinal designs including follow-up into conversion may identify neurocognitive deficits that predict psychosis.

The North American Prodrome Longitudinal Study (NAPLS) is a consortium of 8 research centers, ascertaining CHR individuals and observing them for up to 2½ years. Although originally developed as independent studies, the sites used similar ascertainment and diagnostic methods, making it possible to form a standardized protocol for mapping data into a new scheme representing the common components across sites, yielding the largest database of longitudinally followed CHR cases worldwide.

The primary aims of this study were to characterize the neuropsychology of the psychosis prodrome by comparing performance of CHR individuals with that of normal controls (NCs) and FHR subjects and to examine the value of neuropsychological function for predicting conversion to psychosis. Our hypotheses were that persons who subsequently convert to psychosis are more impaired at baseline than nonconverters, that this effect would be amplified in persons with an FH of psychosis, and that poorer neuropsychological performance would predict more rapid conversion to psychosis.

METHODS

Sample

Study protocols and informed consent documents, including procedures for data pooling and secondary data analysis, were approved by the institutional review boards of the participating sites (Emory University; Harvard University; University of California, Los Angeles [UCLA]; University of California, San Diego [UCSD]; University of North Carolina; University of Toronto; Yale University; and Zucker Hillside Hospital). The NAPLS methods and details of the federated database not specific to the present study are described elsewhere. Nine reports of neuropsychological function have been published on 4 smaller CHR samples by NAPLS centers: 3 from the Prevention Through Risk Identification, Management, and Education (PRIME) multisite study (including Yale, University of North Carolina, and University of Toronto sites); 2 from Zucker-Hillside, and 2 from UCSD. However, these neuropsychological data were not previously combined, did not include a 2-year follow-up (a smaller PRIME study included a 2-year follow-up), and did not evaluate the impact of neuropsychological functioning on conversion to psychosis in relation to FH and other possible predictors.

Participants from the NAPLS database who completed any baseline neuropsychological testing were included, yielding 304 CHR individuals, 52 persons with an FH of psychosis without prodromal symptoms, and 193 NCs without an FH of psychosis or prodromal symptoms. Of the 304 CHR subjects, 269 (88.5%) were observed for up to 2½ years to assess for conversion to psychosis. The 35 CHR participants without any follow-up were excluded from analyses that took conversion status into account. Of the 304 CHR subjects, 89 (29.3%) converted to psychosis, of whom 73 (82.0%) had baseline neurocognitive data.

Assessment Procedures

The Structured Interview for Prodromal Syndromes (SIPS) criteria were used for study entry, and the Structured Clinical Interview for DSM-IV (SCID) was most commonly used to assess general psychopathology. Structured Interview for Prodromal Syndromes criteria for a CHR syndrome emphasize onset or worsening of
attenuated positive symptoms in the past 12 months in at least 1 of 5 symptom domains: unusual thought content, suspicion/paranoia, grandiosity, perceptual anomalies, and disorganized communication. Subjects also qualified for a CHR syndrome if they showed onset of brief intermittent positive psychotic symptoms in the past 3 months but below the threshold required for a DSM-IV Axis I psychotic disorder diagnosis or if they had a genetic risk for psychosis and deterioration of 30% or more on the Global Assessment of Functioning scale in the past 12 months, where genetic risk is defined by having an FH of psychosis or a diagnosis of schizotypal personality disorder.81,82 All NAPLS sites demonstrated good reliability by using the Structured Interview for Prodromal Syndromes criteria (k values ranged from 0.80 to 1.00 across sites).37 At each site, raters were MA, PhD, or MD specialists in mental health.

**FOLLOW-UP ASSESSMENTS**

The Structured Interview for Prodromal Syndromes was readministered at 6-month intervals up to 30 months. If clinical deterioration was observed during interim periods, a reassessment was conducted before regularly scheduled assessments. Because treatment was not standardized, information on dosing and duration of antipsychotic treatments was unavailable for the majority of cases.

**BASELINE NAPLS NEUROPSYCHOLOGICAL ASSESSMENT PROTOCOL**

Cognitive performance variables presented unique challenges in the development of an omnibus protocol.65 Sixty-eight neurocognitive measures derived from 40 separate tests were used across sites. Criteria for test inclusion in the federated database included the following: (1) representation across at least 4 sites; (2) comparability of test versions, administration procedures, and scoring; and (3) coverage of presumed areas of separable cognitive impairment in schizophrenia.63 Thirteen cognitive variables, derived from 8 tests, were initially selected for the omnibus battery. However, to enhance comparability, to carry out multivariate statistical analyses, and to create a composite score for use in prediction analyses, the number of variables examined in these analyses was reduced to 8: Vocabulary,64-67 measuring verbal comprehension; Block Design,64-66 measuring visual-perceptual organization; Continuous Performance Test–Identical Pairs (CPT-IP) digits,68 measuring vigilance; Digit Symbol– Coding (hereinafter referred to as “Coding”),69,70 measuring visual-perceptual organization; Wisconsin Card Sorting Test (WCST),71,72 for problem solving; Controlled Oral Word Association (COWA) test70 for verbal fluency and Wisconsin Card Sorting Test1,72 for problem solving, both measures of executive functioning; and a verbal learning and memory variable, consisting of story recall tests from the Wechsler Memory Scale33,74 for participants 17 years or older and Children’s Memory Scale33 for those younger than 17 years, as well as list learning on the Hopkins Verbal Learning Test–Revised,72 Rey Auditory Verbal Learning Test,72 and California Verbal Learning Test adult and child versions.72,73 Additional information regarding variable construction is available in an online supplement (available at http://www.archgenpsychiatry.com).

**DATA ANALYTIC PLAN**

Data analyses consisted of 2 approaches: a univariate approach that included all subjects for whom data were available in an individual cognitive domain and a multivariate approach that included all cognitive domains and construction of a composite score. To support the multivariate approach, a series of decision rules for acceptable subject inclusion were created and imputation steps were implemented. This resulted in a multivariate sample (n=325) that is a subset (59.2%) of the univariate sample (n=549), including reduced samples of CHR subjects (167 subjects [53% of the CHR subjects in the univariate sample]), FHR (49 [94%]), and NCs (109 [56%]). Because of substantial subject loss in the multivariate sample, both samples were analyzed and compared. The univariate analyses are presented in an online supplement, and significant findings are integrated within the “Results” section.

**Formation of the Multivariate Sample**

Inclusion in the multivariate sample required subjects to have a minimum of 75% complete data (ie, completed at least 6 of 8 tests), thus reducing the total missing data to less than 10%, which was our maximum threshold for data loss before imputation. Multiple imputation methods were used to address missing data. In contrast to listwise deletion, which has the disadvantages of loss of observations and reduced statistical power, multiple imputation permits analysis of complete data by calculating estimates of missing values with the use of other variables in the model as predictors.60,85 Details of the data imputation methods are in the online supplement.

**Group Contrasts**

The groups compared were CHR, FHR, and NC. The CHR group was further subdivided into converters to psychosis (CHR+) and nonconverters (CHR–). Six comparisons were made within both the multivariate and univariate samples: (1) CHR vs NC, (2) FHR vs NC, (3) CHR vs FHR, (4) CHR+ vs NC, (5) CHR– vs NC, and (6) CHR+ vs CHR–. A small subgroup of CHR+ with a positive FH (CHR+ FH+) were analyzed within the univariate sample because of its larger CHR+ FH+ subsample.

**Statistical Analyses**

Statistical analyses were performed with SPSS version 17 (SPSS Inc, Chicago, Illinois) or SAS version 9.1 (SAS Institute Inc, Cary, North Carolina) statistical software. One-way analysis of variance and χ2 tests were conducted to compare groups on demographics. For the multivariate sample, neuropsychological measures were compared by multivariate analysis of variance (MANOVA), multivariate analysis of covariance (MANCOVA), univariate analysis of covariance, and profile analysis. In some contrasts, groups were significantly different on education, parental education, sex, and ethnicity. Because ethnicity and parental education were correlated and because parental education is strongly associated with neurocognition, parental education was controlled for. In contrast, subjects’ own education is likely to be affected by illness and was not controlled for. Because small differences in age can influence neuropsychological functioning in adolescence, analyses controlled for age as well as parental education and sex. We also tested for the effects of site. To examine whether neuropsychological impairments were significant beyond general intellectual impairment, we used MANCOVA controlling for age, sex, and full-scale IQ (FSIQ) estimate (after removing Vocabulary and Block Design tests that compose estimated FSIQ from the profiles). To test whether the shape of neuropsychological profiles differed for selected contrasts, unadjusted scores were analyzed by means of the general linear model repeated-measures function. For profile analyses, the 8 measures were standardized against the NCs within each of the 5 imputed data sets and then pooled across imputed data sets. In addition, a composite score was constructed as the mean of the 8 standardized scores within each imputed data set and then pooled.

Statistical significance was set at P<.05 by means of 2-tailed tests for multivariate analyses (MANOVA, MANCOVA, profile
identical to those of Woods et al for the CHR (n=377) and NC (n=196) groups. Seeking help, they were included in a help-seeking comparison group. Other than that difference, our original groups from which tested subjects were drawn are not significantly lower in the CHR than other groups. Parental education was significantly lower in the CHR group than NCs. The FHR group showed significantly less parental education than NCs. The CHR group had significantly fewer females than the FHR and NC groups. The groups differed on race, with significantly more whites in the CHR than other groups. Parental education was significantly lower in the CHR+ than CHR− subgroup.

Table 1. Demographic Characteristics of the Multivariate Sample

<table>
<thead>
<tr>
<th>Test Statistic (P Value)</th>
<th>CHR Conversion to Psychosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y [n]</td>
<td>CHR+</td>
</tr>
<tr>
<td>Subject education, mean (SD) [n]</td>
<td>18.2 (4.9) [167]</td>
</tr>
<tr>
<td>Parental education, mean (SD) [n]</td>
<td>10.4 (3.1) [196]</td>
</tr>
<tr>
<td>Female sex, No. (%)</td>
<td>60/167 (35.9)</td>
</tr>
<tr>
<td>Race, No. (%)</td>
<td>139/167 (83.2)</td>
</tr>
<tr>
<td>White</td>
<td>15/167 (9.0)</td>
</tr>
<tr>
<td>African American</td>
<td>6/167 (3.6)</td>
</tr>
<tr>
<td>Latino/Latina ethnicity, No. (%)</td>
<td>23/156 (14.7)</td>
</tr>
</tbody>
</table>

Abbreviations: CHR, clinical high-risk; CHR+, CHR subjects who converted to psychosis; CHR−, CHR nonconverters; FHR, family high-risk; NC, normal control.

Demographic comparisons were the same in the univariate and multivariate sample comparisons with the following additions: (1) parental education was significantly lower in the CHR group than in NCs; (2) there were significantly fewer African Americans in the CHR than other groups; (3) the FHR group had significantly fewer Asian Americans than other groups; and (4) the CHR+ and CHR− subgroups did not differ significantly on any variable (eTable 1).

The 167 CHR subjects in the multivariate sample did not differ significantly on any demographic variable from the additional 137 CHR subjects who together formed the univariate sample. (Results are available on request from the first author.)

NEUROPSYCHOLOGICAL FUNCTIONING

Univariate Sample

Multivariate. Raw data are presented in Table 2 and statistical results in Table 3. The MANOVA and MANCOVA for the 8 tests were statistically significant. The MANCOVA, controlling for FSIQ (covariate effect; F=0.26, P=0.62, d=0.16), was significant, and Coding (d=0.56), Verbal Memory (d=0.45), CPT-IP (d=0.39), and the composite score (d=0.45) were significant. See Figure 1 for profile.

Univariate. Raw data are presented in eTable 2 and results in eTable 3. Significant tests were Coding (d=0.38), Verbal Memory (d=0.54), COWA (d=0.47), and CPT-IP digits (d=0.43).

©2010 American Medical Association. All rights reserved.
Table 2. Neuropsychological Test Scores for the Multivariate Sample

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=167)</td>
</tr>
<tr>
<td></td>
<td>(n=49)</td>
</tr>
<tr>
<td></td>
<td>(n=109)</td>
</tr>
<tr>
<td></td>
<td>(n=54)</td>
</tr>
<tr>
<td></td>
<td>(n=113)</td>
</tr>
<tr>
<td>WIS FSIQ</td>
<td>105.4 (1.50)</td>
</tr>
<tr>
<td>Vocabulary</td>
<td>11.3 (0.28)</td>
</tr>
<tr>
<td>Block Design</td>
<td>10.8 (0.28)</td>
</tr>
<tr>
<td>Coding</td>
<td>8.8 (0.27)</td>
</tr>
<tr>
<td>TMT-B, s</td>
<td>68.9 (3.30)</td>
</tr>
<tr>
<td>CPT-IP Digits d′</td>
<td>1.35 (0.08)</td>
</tr>
<tr>
<td>WCWA raw score</td>
<td>34.9 (0.85)</td>
</tr>
<tr>
<td>WCST Perseverative Errors</td>
<td>8.4 (0.36)</td>
</tr>
<tr>
<td>Verbal Memory, z scorec</td>
<td>−0.54 (0.11)</td>
</tr>
<tr>
<td>Composite score, z scoreh</td>
<td>−0.33 (0.06)</td>
</tr>
</tbody>
</table>

Table 3. Contrast Analyses for the Multivariate Sample Including Adjustments for Demographic Characteristics, IQ, and Site (F Values)

<table>
<thead>
<tr>
<th>Variable</th>
<th>CHR vs NC</th>
<th>FHR vs NC</th>
<th>CHR vs FHR</th>
<th>CHR + vs NC</th>
<th>CHR− vs NC</th>
<th>CHR + vs CHR−</th>
</tr>
</thead>
<tbody>
<tr>
<td>WIS FSIQ</td>
<td>0.26</td>
<td>8.76</td>
<td>4.07</td>
<td>2.34</td>
<td>0.05</td>
<td>1.90</td>
</tr>
<tr>
<td>Composite score</td>
<td>9.29b</td>
<td>8.19d</td>
<td>0.07</td>
<td>17.14a</td>
<td>3.40</td>
<td>6.30c</td>
</tr>
<tr>
<td>MANOVA</td>
<td>4.87a</td>
<td>4.56a</td>
<td>4.42b</td>
<td>4.59b</td>
<td>3.95b</td>
<td>1.91c</td>
</tr>
<tr>
<td>MANCOVA</td>
<td>3.72b</td>
<td>3.71b</td>
<td>4.17b</td>
<td>3.49b</td>
<td>3.09b</td>
<td>1.83</td>
</tr>
<tr>
<td>Vocabulary</td>
<td>0.47</td>
<td>10.15b</td>
<td>5.32c</td>
<td>6.19b</td>
<td>0.43</td>
<td>7.80b</td>
</tr>
<tr>
<td>Block Design</td>
<td>0.19</td>
<td>3.25</td>
<td>2.16</td>
<td>0.49</td>
<td>0.05</td>
<td>0.14</td>
</tr>
<tr>
<td>Coding</td>
<td>15.25b</td>
<td>11.42b</td>
<td>0.16</td>
<td>14.24a</td>
<td>9.86b</td>
<td>1.25</td>
</tr>
<tr>
<td>TMT-B, s</td>
<td>1.99</td>
<td>3.64</td>
<td>0.08</td>
<td>6.52c</td>
<td>0.10</td>
<td>5.23c</td>
</tr>
<tr>
<td>CPT-IP Digits d′</td>
<td>9.02b</td>
<td>2.24</td>
<td>1.07</td>
<td>8.43d</td>
<td>5.75c</td>
<td>0.62</td>
</tr>
<tr>
<td>WCWA raw score</td>
<td>9.94b</td>
<td>6.78c</td>
<td>0.26</td>
<td>11.83a</td>
<td>4.93c</td>
<td>2.42</td>
</tr>
<tr>
<td>WCST Perseverative Errors</td>
<td>0.42</td>
<td>2.59</td>
<td>2.84</td>
<td>3.00</td>
<td>2.64</td>
<td>6.33c</td>
</tr>
<tr>
<td>Verbal Memory</td>
<td>9.41b</td>
<td>0.94</td>
<td>8.49b</td>
<td>14.35b</td>
<td>4.97c</td>
<td>2.43</td>
</tr>
<tr>
<td>MANCOVA</td>
<td>5.59b</td>
<td>2.18</td>
<td>3.49b</td>
<td>4.69b</td>
<td>4.34b</td>
<td>1.39</td>
</tr>
<tr>
<td>MANCOVA</td>
<td>5.62b</td>
<td>3.97b</td>
<td>4.14b</td>
<td>4.91b</td>
<td>4.24b</td>
<td>1.46</td>
</tr>
</tbody>
</table>

Abbreviations: CHR, clinical high-risk; CHR+, CHR subjects who converted to psychosis; CHR−, CHR nonconverters; COWA, Controlled Oral Word Association; CPT-IP Digits d′, Continuous Performance Test–Identical Pairs (digits) signal detection measure of discriminability; FHR, family high-risk; NC, normal control; TMT-B, Trail Making Test Part B; WCST, Wisconsin Card Sorting Test; WIS FSIQ, Wechsler Intelligence Scale full-scale IQ estimate.

a Analysis of covariance covarying sex, age, and parental education.
b Dependent variables: Vocabulary, Block Design, Coding, TMT-B, CPT-IP, COWA, WCST Perseverative Errors, and Verbal Memory.

c Dependent variables: Vocabulary, Block Design, Coding, TMT-B, CPT-IP, COWA, WCST Perseverative Errors, and Verbal Memory; covariates: sex, age, and parental education.

d Mean standardized score of the 8 measures (excluding WIS FSIQ).

FHR vs NCs

Multivariate. The MANOVA and MANCOVA were statistically significant. The MANCOVA controlling for FSIQ (co-variate effect; F=8.76, P=.004, d=0.70) was not significant.

Vocabulary (d=0.70), Coding (d=0.66), and the composite score (d=0.75) were significant. See Figure 1 for profile.

Univariate. Significant tests were Vocabulary (d=0.89), Coding (d=0.66), and COWA (d=0.59).
CHR vs FHR

Multivariate. The MANOVA and MANCOVA were statistically significant. The MANCOVA controlling for FSIQ (covariate effect; $F=4.07, P=.045, d=0.44$) was significant. Verbal Memory ($d=0.40$) was significant. The composite score was not significant ($d=0.16$). When CHR and FHR were compared, a test $\times$ group interaction was observed ($F=4.99, P<.001$), indicating a differential (ie, nonparallel) pattern of scores (Figure 1). There was no main effect for group, indicating comparable overall performance ($F=0.06, P=.82$). Table 3 shows that the differential pattern of performance is accounted for by the FHR group exhibiting somewhat greater impairment on Vocabulary, while the CHR group exhibited significantly greater impairment in Verbal Memory.

Univariate. No tests were significantly different.

CHR+ vs NCs

Multivariate. The MANOVA and MANCOVA were statistically significant. The MANCOVA controlling for FSIQ (covariate effect; $F=2.34, P=.13, d=0.34$) was significant. Coding ($d=0.69$), Verbal Memory ($d=0.65$), Vocabulary ($d=0.50$), and the composite score ($d=0.72$) were significant. See Figure 1 for profile.

Univariate. Verbal Memory ($d=0.79$), Coding ($d=0.68$), COWA ($d=0.68$), Vocabulary ($d=0.65$), and CPT-IP digits ($d=0.62$) were significant.

CHR− vs NCs

Multivariate. The MANOVA and MANCOVA were statistically significant. The MANCOVA controlling for FSIQ (covariate effect; $F=1.90, P=.17, d=0.26$) was not significant. The composite score ($d=0.40$) and Vocabulary ($d=0.46$) were significant. A test of profile shape showed no significant test $\times$ group interaction ($F=1.65, P=.14$). A main effect of test was observed ($F=8.56, P<.001$), indicating that differential performance was observed across tests, independent of the groups. In addition, there was a main effect of group, indicating that the profiles differed in overall neuropsychological performance ($F=6.47, P=.01$). See Figure 1.

Univariate. Vocabulary was significant ($d=0.43$).

CHR+FH+ vs NCs

Multivariate. Because the sample was small (CHR+FH+ maximum, n=13), only the univariate sample data were analyzed. Statistically significant, large effects were obtained on Verbal Memory ($d=0.99$), CPT-IP digits ($d=0.98$), and Coding ($d=0.87$). The overall mean ES, weighted for the sample size for each test, suggested a dose response and was largest in the CHR+FH+ group (Figure 2).

Site. Although group ascertainment differed significantly by site (see online supplement), MANCOVAs using site showed minimal impact, affecting only 1 of 6 contrasts (CHR+ vs CHR−; Table 3).

©2010 American Medical Association. All rights reserved.

Figure 1. Neuropsychological profiles of the clinical high-risk (CHR), CHR converter (CHR+), CHR nonconverter (CHR−), and family high-risk (FHR) groups standardized against the normal control (NC) group from the multivariate sample. COWA indicates Controlled Oral Word Association; CPT-IP, Continuous Performance Test–Identical Pairs; TMT-B, Trail Making Test Part B; and WCST, Wisconsin Card Sorting Test.

Figure 2. Effect sizes reflecting comparisons of different high-risk groups with normal controls. Effect sizes (Cohen d) are averaged within group in the univariate sample after weighting for sample size across the 8 neuropsychological test variables. Data suggest a dose-response impact of both conversion and family history of psychosis. Groups are as follows (average number of subjects per test per group in parentheses): normal controls (n=144), clinical high-risk (CHR) nonconverters (CHR−) (n=155), CHR (total sample) (n=242), family high-risk (FHR) (n=45), CHR converters (CHR+) (n=62), and CHR+ with positive family history (CHR+FH+) (n=13).
Sensitivity of Individual Tests. Twelve of 48 tests (25%) in the multivariate sample and 16 of 48 tests (33%) in the univariate sample (which included 45% more subjects) were statistically significant at the Bonferroni level. Coding was significant 4 of 6 times and Verbal Memory was significant 3 of 6 times in each sample, indicating that they were most likely to show impairment. Block Design, Trail Making Test Part B, and Wisconsin Card Sorting Test perseverative errors were not significant at the Bonferroni level in any comparisons, suggesting that they are less affected in high-risk samples.

**Prediction of Progression to Psychosis With Neuropsychological Tests.** Cox regression models were estimated to identify baseline cognitive variables that were most predictive of time to conversion to psychosis. In the first set of analyses, only 4 selected variables were examined. The composite score ($\chi^2=3.05, P=.08$), FSIQ ($\chi^2=2.63, P=.11$), and Coding ($\chi^2=0.14, P=.71$) were not significant. In contrast, Verbal Memory was a significant predictor of time to conversion ($\chi^2=6.1, P=.01$) and demonstrated a hazard ratio of 0.79, suggesting that CHR subjects with impaired verbal memory were likely to progress to psychosis more rapidly. A second analysis used backward selection to identify which among the 8 cognitive variables were the best predictors of rate of progression to psychosis. The log-rank test was not significant ($\chi^2=13.18, P=.11$). A third Cox regression examined whether the cognitive variables (composite, FSIQ, Coding, and Verbal Memory) added to the multivariate NAPLS prediction model. None contributed uniquely to the prediction of psychosis beyond clinical variables.

**Table 4. Effect Sizes (Unadjusted Cohen d) for Persons Who Later Develop Psychosis or Schizophrenia From Premorbid and CHR (Converters) Phases and Persons With First-Episode Schizophrenia**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Premorbid</th>
<th>CHR− (n=113)</th>
<th>CHR+ (n=54)</th>
<th>No. of NC</th>
<th>CHR− (No.)</th>
<th>CHR+ (No.)</th>
<th>First Episode</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-scale IQ</td>
<td>−0.54</td>
<td>−0.07</td>
<td>−0.34</td>
<td>173</td>
<td>−0.19 (171)</td>
<td>−0.46 (71)</td>
<td>−1.01</td>
</tr>
<tr>
<td>Vocabulary</td>
<td>−0.03</td>
<td>−0.50</td>
<td>−0.50</td>
<td>182</td>
<td>−0.18 (187)</td>
<td>−0.65 (71)</td>
<td>−0.94</td>
</tr>
<tr>
<td>Block Design</td>
<td>−0.08</td>
<td>−0.20</td>
<td>−0.30</td>
<td>182</td>
<td>−0.09 (166)</td>
<td>−0.22 (66)</td>
<td>−0.90</td>
</tr>
<tr>
<td>Coding</td>
<td>−0.50</td>
<td>−0.69</td>
<td>−0.69</td>
<td>109</td>
<td>−0.57 (139)</td>
<td>−0.68 (63)</td>
<td>−1.59</td>
</tr>
<tr>
<td>TMT-B</td>
<td>−0.13</td>
<td>−0.49</td>
<td>−0.49</td>
<td>113</td>
<td>−0.17 (135)</td>
<td>−0.48 (59)</td>
<td>−0.91</td>
</tr>
<tr>
<td>CPT-IP Digits d'</td>
<td>−0.38</td>
<td>−0.43</td>
<td>−0.43</td>
<td>158</td>
<td>−0.39 (135)</td>
<td>−0.62 (48)</td>
<td>−0.71c</td>
</tr>
<tr>
<td>COWA raw score</td>
<td>−0.40</td>
<td>−0.65</td>
<td>−0.65</td>
<td>116</td>
<td>−0.40 (144)</td>
<td>−0.68 (62)</td>
<td>−0.69</td>
</tr>
<tr>
<td>WCST Perseverative Errors</td>
<td>−0.08</td>
<td>−0.28</td>
<td>−0.28</td>
<td>101</td>
<td>−0.17 (155)</td>
<td>−0.43 (58)</td>
<td>−0.81</td>
</tr>
<tr>
<td>Verbal Memory</td>
<td>−0.35</td>
<td>−0.65</td>
<td>−0.65</td>
<td>191</td>
<td>−0.46 (179)</td>
<td>−0.79 (67)</td>
<td>−1.41</td>
</tr>
</tbody>
</table>

Abbreviations: CHR, clinical high-risk; CHR+, CHR subjects who converted to psychosis; CHR−, CHR nonconverters; COWA, Controlled Oral Word Association; CPT-IP Digits d', Continuous Performance Test–Identical Pairs (digits) signal detection measure of discriminability; NC, normal control; TMT-B, Trail Making Test Part B; WCST, Wisconsin Card Sorting Test.

©2010 American Medical Association. All rights reserved.

©2010 American Medical Association. All rights reserved.
ence of deficits of any severity. However, because most clinical neuropsychological tests are multifactorial, more refined cognitive neuroscience measures are needed to determine which cognitive mechanisms are impaired.

From a staging perspective, as further explicated in Table 4, neurocognitive deficit apparently increases in severity from prodrome to first episode, and this growing impairment is accompanied by increasing executive dysfunction. This suggests that additional neuropsychological deterioration in those developing psychosis may continue to occur during the late prodromal phase and possibly during and subsequent to the first episode of psychosis. However, this proposition can be addressed definitively only in longitudinal studies that monitor cognitive function in the same subjects. The literature on this issue is sparse, with only 1 published study having similar neuropsychological data collected relatively close to and after the first episode; significant decline was reported on 2 of the 4 tests. A major strength of this study is its large sample size, larger at baseline and follow-up than any previously published study of neurocognition in CHR individuals. Few published reports on CHR have included neuropsychological functioning in persons who convert to psychosis. With the exception of the Melbourne (n=34) and German (n=44) projects, sample sizes are small (<21 converters). Thus, this study, which compared neuropsychological functioning on as many as 71 converters, provides the most robust data indicating that persons who later convert to psychosis are especially impaired at baseline (composite score d=0.72). While the overall (composite score) ES difference between the CHR+ and CHR− groups was modest (d=0.40), the effect was consistent in that CHR− subjects performed worse than CHR− subjects on all 8 neuropsychological measures. On the basis of the Cox regression analyses, only verbal memory was associated with a significant decrease in time to conversion. When the 8 neuropsychological variables, FSIQ, or the composite score were added separately to the multivariate NAPLS prediction algorithms, none of the prediction statistics for the neurocognitive variables was significant, indicating that none added unique variance to prediction beyond clinical variables. It remains possible that future large-scale studies that include a uniformly broader range of neuropsychological tests, particularly measures of olfaction and working memory (shown in previous studies to be associated with conversion but unavailable in this data set), may add unique predictive power to risk algorithms.

The neuropsychological functioning of the FHR sample was consistent with the extant literature, yielding ES differences of 0.20 to 0.70 for many functions. This suggests that a modest proportion of the variance in neuropsychological function is putatively associated with genetic factors, presumably expressing themselves through brain dysfunction. What is striking about our findings is that CHR and FHR had different patterns of impairment, and thus FHR may contribute additional cognitive impairments to CHR status. This was observed in the larger ESs in the CHR+FH+ subgroup, although small sample size precludes firm conclusions. We found only 2 studies that linked FH and conversion to psychosis, the Edinburgh and Palau high-risk studies. These studies used very different designs and ascertainment criteria, making findings difficult to integrate. Nonetheless, both studies show a trend for persons with FHR plus prodromal symptoms to be particularly neuropsychologically impaired.

This study has a number of limitations, the most important being variability in the specific tests administered across NAPLS sites resulting in relatively high rates of missing data for some measures and inconsistent sample sizes across tests. We addressed this problem by creating a multivariate sample in which we reduced the number of tests and subjects and then imputed data. Although this resulted in substantial subject loss, we were able to demonstrate that the results were consistent across the smaller multivariate subsample and the full univariate sample as observed by comparable ESs (see Table 4). We also constrained our conclusions about individual tests with Bonferroni corrections. Another limitation was the domains assessed (eg, social cognition, olfaction, and other measures of executive function were not assessed). Future work should combine large samples with a common neuropsychological battery, selected to maximize predictive value. In addition, because it is likely that some CHR subjects will convert to psychosis later, “misclassifying” some subjects as nonconverters may have reduced the differences observed in CHR+ and CHR− contrasts. Subjects were followed up for variable periods, but even a 2.5-year follow-up duration is unlikely to identify all persons who convert. We also had limited data on medication status and other treatment exposures. It will be important in future CHR studies to account for the effects of psychopharmacologic and other treatments.

Despite these limitations, our study is largely consistent with the results of other research groups, including those comparing converters with nonconverters. These findings document that prospective ascertainment of individuals at CHR of psychosis demonstrates significant neuropsychological impairment, especially among those who later convert to psychosis, and these effects are amplified among those with an FH of psychosis. Because neuropsychological tests are relatively inexpensive, have extensive normative data, and are heavily used by school personnel, in conjunction with FH and attenuated clinical symptoms, they may have potential as early indicators of risk of psychosis as well as other important outcomes such as functional disability.

Submitted for Publication: July 13, 2009; final revision received November 10, 2009; accepted November 18, 2009.

Author Affiliations: Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center (Drs Seidman, Giuliano, and Tsuang) and Massachusetts General Hospital, Boston (Drs Seidman and Tsuang); Department of Psychiatry and Behavioral Science, Texas A&M Health Science Center, College of Medicine, Waco (Dr Meyer); Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada (Dr Addington); Department of Psychiatry, University of California, San Diego (Drs Cadenhead, Tsuang, and Heaton); Departments of Psychology and Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Drs Cannon and Bearden); Department of Psychiatry, Yale University, New Haven, Connecticut (Drs McGlashan, Woods, and Hawkins); Department of Psychology, University of North Carolina, Chapel Hill (Dr Perkins); Departments of Psychology and Psychiatry, Emory...
University, Atlanta, Georgia (Dr Walker); Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, Ontario, Canada (Dr Christensen); Department of Psychiatry & Behavioral Sciences and Psychology, Duke University, Chapel Hill (Dr Keefe); Schizophrenia Spectrum Research Program, Division of Adult Translational Research, National Institute of Mental Health, Bethesda, Maryland (Dr Heinssen); and Department of Psychiatry, Zucker Hillside Hospital, Long Island, New York (Dr Cornblatt).

Correspondence: Larry J. Seidman, PhD, Department of Psychiatry, Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, 401 Park Dr, Boston, MA 02215 (lseidman@bidmc.harvard.edu).

NAPLS Group Members: Jean Addington, PhD, Diane Kirsopp, BA, Ivana Furimsky, MN, Irvin Epstein, MD, and Robert Zipursky, MD (Toronto, Ontario, Canada); Donald Addington, MD, and Anna Gresko, BN (Calgary, Alberta, Canada); Kristin Cadenhead, MD, Kathleen Shafer, BS, Iliana Marks, MA, Katherine Seебer, MD, Nsara Haroun, MD, and Karin Kristensen, PsyD (UCSD); Tyrone Cannon, PhD, Jennifer Johnson, PhD, Carrie Bearden, PhD, Mary O’Brien, PhD, Melita Daley, MD, Tara Niemand, PhD, and Jamie Zinberg, MA (UCLA); Barbara Correll, PhD, MBA, Christopher Smith, PhD, Andrea Ausher, PhD, Pradeep Nagachandran, MD, and Joshua Biener, BA (Zucker Hillside Hospital); Diana O. Perkins, MD, MPH, Jennifer Nieri, MSW, LCSW, and Karen Graham, MD (University of North Carolina); Larry Seidman, PhD, Ming Tsuang, MD, PhD, Anthony Giuliano, PhD, Eric Meyer, PhD, and Lynda Tucker (Harvard University); Elaine Walker, PhD, and Shivali Dhruv, BA (Emory University); Scott Woods, MD, Thomas McGlashan, MD, Tandy Miller, PhD (deceased), Roy Money, MS, and Philip Markovich, BA (Yale University); and Robert Heinssen, PhD (National Institute of Mental Health).

Financial Disclosure: Dr Seidman has received investigator-initiated research funding support from multiple for-profit entities including the National Institute of Mental Health, the National Institute on Aging, the Commonwealth of Massachusetts Department of Mental Health, the National Alliance for Research on Schizophrenia and Depression (NARSAD), and the Sidney R. Baer Jr. Foundation. He has not received funding from for-profit entities in the past 12 months. In the past he received unrestricted educational support from Janssen Pharmaceuticals and has served as a consultant for Shire. Dr Giuliano has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health and NARSAD. Dr Meyer has received investigator-initiated research funding support from the US Department of Veterans Affairs. Dr Addington has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health and NARSAD. Dr Meyer has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health, Ontario Mental Health Foundation, and the Schizophrenia Society of Ontario. Dr Addington has served as a consultant for Pfizer, AstraZeneca Pharmaceuticals, and Janssen Pharmaceuticals. Dr Cadenhead has received investigator-initiated research funding support from the National Institute of Mental Health. Dr Cannon has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health, NARSAD, and the Staglin Music Festival for Mental Health. Dr Cannon has served as a consultant for Janssen Pharmaceuticals and Eli Lilly and Company. Dr McGlashan has received investigator-initiated research funding support from the National Institute of Mental Health, the Personality Disorder Research Foundation, and Eli Lilly and Company. Dr McGlashan has served as a consultant for Eli Lilly and Company, Pfizer, Solvay/Wyeth, and Roche Pharmaceuticals. Dr Perkins has received research funding from Janssen Pharmaceuticals and Dainippon Sumitomo Pharma in the past 12 months. In the past Dr Perkins received research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Otsuka Pharmaceutical Co Ltd, Eli Lilly and Company, Janssen Pharmaceuticals, and Pfizer and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceuticals, GlaxoSmithKline, Forest Labs, Pfizer, and Shire. Dr Tsuang has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health and has received research grants from Janssen Pharmaceuticals. Dr Walker has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health and NARSAD. She has not received funding from for-profit entities. Dr Woods has received investigator-initiated research funding support from multiple not-for-profit entities including the National Institute of Mental Health, the Donaghue and Stanley foundations, and NARSAD. In addition, he has received investigator-initiated research funding support from multiple for-profit entities including UCB Pharma and Bristol-Myers Squibb and has consulted for Otsuka and Schering-Plough. Dr Woods has not served on speaker’s bureaus. Dr Bearden has received investigator-initiated research funding support from the National Institute of Mental Health. She has not received funding from for-profit entities in the past 12 months. Dr Christensen has received investigator-initiated research funding support from multiple not-for-profit entities including the Canadian Institutes of Health Research, Ontario Neurotrauma Foundation, and Ontario Mental Health Foundation. He has not received funding from for-profit entities in the past 12 months. In the past he received research support from Eli Lilly and Company and has served as a consultant for Janssen Pharmaceuticals. Dr Hawkins has received funding support from the National Institute of Mental Health, the Alzheimer’s Disease Association, and the Department of Mental Health and Addiction Services of the State of Connecticut. Dr Heaton has received investigator-initiated funding from the National Institute of Mental Health, the National Institute on Drug Abuse, and the National Institute of Neurological Disorders and Stroke. Dr Keefe has received investigator-initiated research funding support from the National Institute of Mental Health and the Singapore National Medical Research Council and an unrestricted educational grant from AstraZeneca Pharmaceuticals. He has received honoraria or served as a consultant or advisory board member for Abbott Laboratories, AstraZeneca Pharmaceuticals, BiolineRx, Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo Pharma, Eli Lilly and Company, Johnson & Johnson, Lundbeck, Memory Pharmaceutical...
cals, Merck, Neurosearch, Orion, Orexigen, Otsuka, Pfizer, Roche, Sanofi-aventis, Shire, Targacept, Wyeth, and Xenonport. In the past, he has received honoraria or served as a consultant or advisory board member for Acadia, Cortex, Cyberonics, Forest, Gabriel, GlaxoSmithKline, Repligen, Saegis, and Schering-Plough and has received research funding from AstraZeneca Pharmaceuticals, Eli Lilly and Company, Janssen Pharmaceuticals, and Pfizer. Dr Keefe receives royalties from the Brief Assessment of Cognition in Schizophrenia (BACS) testing battery and the MATRICS Battery (BACS Symbol Coding). Dr Heinssen is an employee of the nonprofit National Institutes of Health and has had no financial relationships with for-profit entities. Dr Cornblatt has received investigator-initiated research funding support from not-for-profit entities including the National Institute of Mental Health and the Stanley Medical Research Institute. She has also served as a consultant for Eli Lilly and Company, Bristol-Myers Squibb, and Janssen Pharmaceuticals and has received unrestricted educational grants from Janssen Pharmaceuticals.

Funding/Support: This study was supported by the National Institute of Mental Health (grants R18 MH 43518, U01 MH081928, and P50 MH082072 to Dr Seidman; grant U01 MH066134 to Dr Addington; grants R01 MH06720 and K24 MH76191 to Dr Cadenen; grant R01 MH65079 to Dr Cannon; grant K05MH16554 to Dr McGlashan; grants U01 MH06069 and P50 MH064065 to Dr Perkins; grant R18 MH 43518 to Dr Tsuang; grants RO1MH062066 and 5 U01 MH081988 to Dr Walker; grants U01 MH74336, U01 MH82022, and R41 MH083436 to Dr Woods; and grant R01 MH01523 to Dr Cornblatt).

Disclaimer: The views expressed are those of the authors and do not necessarily reflect the official views of the National Institute of Mental Health, the National Institutes of Health, or any other branch of the US Department of Health and Human Services.


Additional Contributions: We acknowledge the substantial contributions of Jennifer Johnson, PhD (UCLA), Diane Kirspop, BA (University of Toronto), and Roy Money, MS (Yale University), to the creation of the federated NAPLS database described in this article.

REFERENCES


23. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry. 2006;11(11-17).


36. Myles-Worsley M, Ord LM, Ngiralmau H, Weaver S, Blalies F, Faraone SV. The...


